What a Compliant Peptide Program Actually Looks Like
Most practices that offer peptides don't have a peptide program. They have a purchasing habit dressed up to look like one.
The difference becomes visible the first time a state board requests documentation. Or a pharmacy partner gets audited. Or a patient outcome generates a complaint and someone starts asking where the compound came from, who manufactured the API, and what the Certificate of Analysis says.
The 503A framework for peptides is more specific than most operators realize, and it has shifted considerably over the past two years. Understanding where a given compound actually sits in that framework is not a compliance exercise. It is the foundation of the entire program.
The first layer most practices get wrong is the supply chain. A 503A pharmacy compounding peptides must source the active pharmaceutical ingredient from an FDA-registered manufacturer. Research-grade suppliers are not FDA-registered manufacturers. That label, "research use only," describes a different category of product operating under a different regulatory framework entirely. Sourcing from that channel and dispensing to patients is not a gray area. It is simply outside the permitted pathway, and the practice absorbs the exposure when something surfaces.
The practices that survive scrutiny are the ones that can reconstruct every link in the chain without gaps.
The second layer is the prescription itself. 503A compounding is patient-specific by definition. A licensed prescriber evaluates a patient, identifies a clinical need that a registered compounding pharmacy can address, and generates a prescription for that specific patient. Compounding in anticipation of orders, or fulfilling prescriptions written without a genuine patient relationship, removes the legal foundation the 503A model is built on.
The third layer is documentation. Certificate of Analysis for each batch. Pharmacy registration status, verified. Prescriber relationship, documented. Clinical rationale, recorded. These are not administrative formalities. They are the record that determines whether the practice can defend what it did if the question ever gets asked.
Practices that have built this infrastructure correctly share one characteristic: they know exactly what their pharmacy can and cannot do, and why. They have read the FDA's bulk substances list. They understand which compounds are permitted, which are under active review, and which have been restricted. They make decisions based on that map, not on what a sales rep told them was available.
That level of operational clarity is rarer than it should be. But it is the only version of a peptide program that holds up over time.
How to Evaluate a Compounding Pharmacy Before You Need To
Most practices choose a compounding pharmacy the same way they choose any vendor. Price, proximity, a referral from someone they trust. The relationship runs quietly in the background until something goes wrong, and then it becomes the most important operational decision the practice ever made.
The problem with that approach is that by the time something goes wrong, the evaluation window has closed. A pharmacy audit, a patient complaint, a board inquiry. Those are not moments for discovering that your partner's registration was lapsed, or that the COA they provided was for a different batch, or that the API they sourced wasn't from an FDA-registered manufacturer.
Due diligence on a compounding pharmacy is an operational function, not a one-time credentialing task. The regulatory environment for compounded peptides in particular has shifted enough over the past two years that a pharmacy's status and capabilities from 2022 may not accurately describe what it can compliantly do in 2026.
Vetting a pharmacy after you've already built your program around it is not vetting. It is damage control.
There are a few specific things worth confirming before building a program around any 503A partner. The pharmacy should hold current state licensure and be registered with the FDA if it ships across state lines. It should source all APIs from manufacturers listed with the FDA, and be able to provide that documentation without friction. It should issue a Certificate of Analysis for every batch, from a third-party lab, not an internal quality check. It should have a clear, documented recall process and evidence that it has exercised it.
Beyond the paperwork, the more revealing question is whether the pharmacy understands the current 503A bulk substances list and can speak to where each compound sits on it. The list has changed. Substances that were available two years ago may not be today. Substances that were restricted have had their status shift through the PCAC review process. A pharmacy operating with an outdated picture of that landscape is a pharmacy operating with compliance risk it may not know it is carrying.
The practices running durable peptide programs are not necessarily the ones with the most compounds on offer.
They are the ones whose pharmacy partner treats regulatory literacy as an operational requirement, not a background concern.
Sermorelin remains the clearest example of what a well-grounded program looks like in practice. It has prior FDA approval, a clean sourcing history, and a straightforward path through a licensed 503A pharmacy with a patient-specific prescription. NAD+ follows the same structure. Neither requires navigating uncertainty. Both require the same documentation discipline as anything else in the program.
The compound is not the program. The infrastructure around it is. And the pharmacy is where most of that infrastructure either holds or doesn't.
About the Author
I work at the intersection of clinics, telehealth platforms, pharmacies, and the systems that support them.
I've spent the past decade building and scaling operations across clinics, telehealth platforms, and compounding pharmacies. I've seen practices succeed at 20 patients per month and break at 200. I've watched regulatory shifts reorganize entire markets overnight. I've built the infrastructure that determines whether modern therapies scale or stall.
This newsletter is about understanding how the system actually functions, where friction hides, and why some approaches compound over time while others don't.
If you're building, running, or participating in modern health in any real way, this layer matters more than most people realize.
"The system doesn't care about your intentions. It responds to what you built."
Until next time,
